See all eligibility criteria
See protocol details
The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
are designated in this study
of being blinded to the placebo group